Market Overview

Boston Scientific Receives CE Mark for Vercise Deep Brain Stimulation System


Boston Scientific Corporation (NYSE: BSX) received CE Mark approval for use of its Vercise Deep Brain Stimulation (DBS) System for the treatment of Parkinson's disease.  The Vercise DBS System is the first and only commercially available DBS system to incorporate multiple independent current control, which is designed to selectively stimulate targeted areas in the brain.  This system is an innovative technology that is designed to provide physicians fine control of stimulation.

"The launch of the Vercise™ DBS System represents a key expansion for Boston Scientific," said Maulik Nanavaty, senior vice president and president of Boston Scientific's Neuromodulation Division.  "Vercise DBS is the only system on the market able to finely control stimulation with multiple independent current control.  This unique technology underscores our commitment to improving patients' lives."

The first commercial implant of the Vercise™ DBS System was performed by a team at the University Clinic Wurzburg in Germany that included Prof. Dr. Cordula Matthies, Head of Functional Neurosurgery and Prof. Dr. Jens Volkmann, Director of the Department of Neurology. 

"We welcome the Vercise DBS System," said Prof. Dr. Volkmann.  "We believe it represents advancement in DBS technology through flexible and unique programming options.  We believe

See full press release

Posted-In: News Guidance Global


Related Articles (BSX)

View Comments and Join the Discussion!